Beyond the Lumen: How Intracranial Vessel Wall MRI Is Changing Stroke Etiology Workup

Introduction

Stroke remains one of the leading causes of death and disability worldwide, with intracranial atherosclerotic disease (ICAD) accounting for 30–50% of ischemic strokes in high-risk populations, including Asian, Hispanic, and African American communities. Despite its high prevalence, the diagnosis of ICAD has historically depended on luminal imaging techniques, such as CT angiography, MR angiography, and digital subtraction angiography, that reveal only the degree of arterial narrowing. This approach misses a critical dimension: the arterial wall itself.

Emerging evidence shows that conventional lumen-based imaging fails to identify a substantial proportion of culprit lesions, particularly nonstenosing plaques that can nonetheless trigger embolic stroke. High-resolution vessel wall MRI (VW-MRI) has emerged as a promising adjunctive imaging tool that may complement conventional stroke evaluation in selected patients. It enables direct visualization of intracranial arterial walls, characterization of plaque features, and provides valuable diagnostic and prognostic information that was previously inaccessible. Therefore, this blog reviews the growing evidence supporting VW-MRI as a key component of the modern stroke etiology workup.

Background / Clinical Context

The Limits of Lumen-Based Imaging

Traditional imaging of intracranial vessels focuses on luminal stenosis, grading disease severity by how much the artery is narrowed. While this has been the cornerstone of ICAD evaluation for decades, its predictive value is increasingly being challenged. Importantly, atherosclerotic plaques can undergo positive remodeling, outward expansion of the vessel wall that preserves, luminal diameter while harboring high-risk features such as inflammation, neovascularization, or intraplaque hemorrhage. These nonstenosing plaques are invisible on conventional MRA or CTA, yet accumulating data suggests they represent an important and underrecognized   mechanism of embolic stroke of undetermined source (ESUS).

What VW-MRI Offers

VW-MRI addresses this diagnostic gap by combining high spatial resolution with dedicated blood and CSF signal suppression sequences that render the arterial wall visible. A standard intracranial VW-MRI protocol typically includes time-of-flight MRA, pre- and post-gadolinium T1-weighted black-blood sequences, and T2-weighted sequences. This multicontrast approach enables characterization of multiple plaque features, enhancement, morphology, signal intensity, and remodeling, that correspond to distinct pathological processes including plaque inflammation, fibrous cap rupture, and intraplaque hemorrhage. The small caliber of intracranial arteries makes this technically demanding, requiring sub-millimeter in-plane resolution and strong field strengths (3T), but advances in coil design and sequence optimization have made this clinically feasible.

Key Evidence / Recent Advances

Study 1: VW-MRI Biomarkers of Symptomatic Intracranial Atherosclerosis (Song et al., 2021)

Song et al. conducted a systematic meta-analysis of 21 studies (1,750 lesions; 1,542 subjects) evaluating VW-MRI features of symptomatic ICAD plaques, published in Stroke (2021). The analysis found that plaque enhancement (OR 7.42), positive remodeling (OR 5.60), T1 hyperintensity (OR 2.05), and surface irregularity (OR 4.50) were each significantly associated with stroke attributable to intracranial atherosclerosis. Plaque enhancement was particularly robust, remaining significant across all subgroup analyses regardless of study design, magnetic field strength, or sequence type.

The clinical relevance of these findings is substantial. Collectively, they suggest that vessel wall characteristics provide important diagnostic information beyond luminal stenosis alone.. Plaque enhancement, reflecting neovascularization, inflammation, and endothelial dysfunction, emerged as the single most powerful imaging biomarker. The authors further suggested that vessel wall changes may actually outperform luminal changes in predicting stroke occurrence, shifting the paradigm for how ICAD should be evaluated.

Study 2: VW-MRI Plaque Features Predict Stroke Recurrence (Zhang et al., 2025)

Building on the cross-sectional evidence, Zhang et al. performed a meta-analysis focused specifically on the longitudinal predictive value of VW-MRI features for stroke recurrence, published in European Radiology (2025). Eighteen studies comprising 2,240 participants (472 with recurrent stroke, average 16-month follow-up) were analyzed. Plaque enhancement (OR 2.81), enhancement ratio (SMD 0.46), plaque thickness (SMD 0.27), T1-weighted hyperintensity (OR 2.58), and degree of stenosis (SMD 0.41) all significantly predicted recurrent ischemic stroke (IS) or transient ischemia attack (TIA).

Multivariable analyses across 13 included studies identified T1 hyperintensity, plaque enhancement, plaque burden, and change in plaque enhancement as independent predictors of recurrent cerebrovascular events. Notably, subgroup analyses revealed that plaque enhancement was more strongly predictive in the combined IS+TIA group (OR 3.39), while plaque burden was selectively predictive only in pure IS recurrence. These findings suggest that  VW-MRI may provide clinically meaningful risk stratification beyond conventional luminal assessment and may help identify patients at increased risk of recurrent ischemic events.

Study 3: VW-MRI in Nonstenosing ICAD – A Teaching Case (Del Bello et al., 2024)

Del Bello et al. illustrated the clinical impact of VW-MRI in a compelling teaching case published in Stroke (2024). A 65-year-old man presented with recurrent transient ischemic attacks and multiple acute DWI lesions in the right MCA territory. MRA was negative for significant stenosis, and an initial workup for cardioembolic sources was unrevealing, leading to an initial diagnosis of embolic stroke of undetermined source. VW-MRI performed 14 days post-event identified a focal, eccentric, nonstenosing atherosclerotic plaque in the right proximal MCA with vivid gadolinium enhancement, identifying it as the culprit lesion.

Serial VW-MRI at 3 months showed persistent strong enhancement, prompting extension of dual antiplatelet therapy and intensification of lipid-lowering therapy. At 1 year, enhancement had substantially diminished to only a punctiform focus, and the patient was stepped down to single antiplatelet therapy, without any recurrent stroke over 18 months. This case powerfully demonstrates VW-MRI’s dual role: resolving diagnostic uncertainty and enabling dynamic, evidence-guided treatment decisions over time.

Clinical Implications

The emerging evidence suggests several practice-changing implications for radiologists and clinicians. First, VW-MRI may be considered in selected stroke patients with negative or inconclusive conventional lumen-based imaging, particularly those with a suspected ESUS diagnosis. Nonstenosing intracranial plaques are increasingly recognized as an important and underdiagnosed mechanism of ESUS. VW-MRI is currently the only noninvasive modality capable of detecting and characterizing these lesions.

Second, the identification of high-risk plaque features, especially enhancement and T1 hyperintensity, should influence secondary prevention strategies. Patients with enhancing plaques may warrant longer courses of dual antiplatelet therapy, more aggressive lipid management targeting LDL below 55 mg/dL, and closer clinical follow-up. Third, serial VW-MRI provides a mechanism to monitor plaque response to therapy, guiding de-escalation decisions in a way that was not previously possible. For radiologists, this shifts the reporting paradigm: a complete stroke MRI report in high-risk patients increasingly requires not just luminal assessment but wall characterization.

Key Takeaways

• VW-MRI moves beyond luminal stenosis to directly characterize intracranial plaque features, identifying culprit lesions missed by CTA and MRA, especially nonstenosing plaques in ESUS patients.
• Plaque enhancement is the strongest and most consistent imaging biomarker, associated with both acute symptomatic plaque (OR 7.42) and risk of stroke recurrence (OR 2.81).
• T1 hyperintensity, enhancement ratio, plaque thickness, and degree of stenosis also independently predict recurrence, enabling individualized risk stratification beyond what standard imaging provides.
• Serial VW-MRI can track plaque response to medical therapy, offering objective guidance for treatment duration and intensity in secondary stroke prevention.
• Standardization of VW-MRI protocols and reporting criteria remains an unmet need; radiologists play a pivotal role in advancing this area toward routine clinical integration.

Conclusion

Intracranial vessel wall MRI has evolved from a research-focused technique into a promising clinical imaging tool for the evaluation of cerebrovascular disease. l. By enabling direct visualization of arterial walls, VW-MRI reveals a dimension of cerebrovascular disease that conventional imaging may overlook. From identifying nonstenosing culprit plaques to predicting recurrence risk and monitoring treatment response, this modality offers radiologists and neurologists a new lever in the fight against stroke. As prospective trials mature and imaging protocols become standardized, VW-MRI is poised to become a routine component of the comprehensive stroke workup, particularly in patients where the cause remains elusive after conventional evaluation.

References

1. Song JW, Pavlou A, Xiao J, Kasner SE, Fan Z, Messé SR. Vessel wall magnetic resonance imaging biomarkers of symptomatic intracranial atherosclerosis: a meta-analysis. Stroke. 2021;52(1):193–202. doi:10.1161/STROKEAHA.120.031480
2. Zhang J, Sun B, Wang H, et al. Intracranial atherosclerotic plaque features on vessel wall imaging predict first ever and recurrence of stroke: a meta-analysis. Eur Radiol. 2025;35(8):5017–5026. doi:10.1007/s00330-025-11451-1
3. Del Bello B, Rognone E, Pichiecchio A, Cavallini A, Mazzacane F. Vessel wall MRI in the diagnosis and follow-up of nonstenosing intracranial atherosclerotic lesions in acute stroke. Stroke. 2024;55:e35–e38. doi:10.1161/STROKEAHA.123.044710